Donanemab showed an ability to slow cognitive decline and the loss of daily life abilities in people at earlier stages of Alzheimer’s disease relative to those given a placebo in the Phase 2 TRAILBLAZER-ALZ trial, researchers report. A plaque-targeting therapy, donanemab also cleared substantial amounts of amyloid plaques in the brains of treated patients. But outcomes in secondary trial goals — measures of cognition, memory, and activities of daily living — were more mixed and further study recommended.…
You must be logged in to read/download the full post.
The post Donanemab Shows Potential for Early Alzheimer’s in Phase 2 Trial appeared first on BioNewsFeeds.